Denver、COにおける悪性黒色腫の臨床試験
Denverとその周辺地域（約30マイル以内）の拠点で、悪性黒色腫に関する19件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- AdventHealth Porter, Denver
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
被験者募集中第1相
- Presbyterian/St Lukes Medical Center, Denver
- Sarah Cannon Research Institute at HealthONE, Denver
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
被験者募集中第3相
- The Melanoma And Skin Cancer Institute, Englewood · 6マイル先
Pan-tumor MRD Study
被験者募集中観察研究
- The Melanoma and Skin Cancer Institute, Englewood · 6マイル先
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute, Denver
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
被験者募集中第2相
- The Women's Imaging Center, Denver
- Colorado Blood Cancer Institute, Denver
- Presbyterian - Saint Lukes Medical Center - Health One, Denver
- 他6件
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
被験者募集中第1/2相
- Skin Cancer Institute, Englewood · 6マイル先
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute Denver, Denver
Project: Every Child for Younger Patients With Cancer
被験者募集中観察研究
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
被験者募集中第1/2相
- SCRI Oncology Partners- Denver, Denver
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
被験者募集中第1/2相
- SCRI - Denver, Denver
Neoadjuvant Darovasertib in Primary Uveal Melanoma
被験者募集中第3相
- The Melanoma and Skin Cancer Institute, Englewood · 6マイル先
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
被験者募集中第2/3相
- University of Colorado, Denver
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute at Health ONE, Denver
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
被験者募集中第2/3相
- The Melanoma & Skin Cancer Institute, Englewood · 6マイル先
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- Kaiser Permanente-Franklin, Denver
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Centers-Midtown, Denver
- 他1件
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Denver
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
被験者募集中第1/2相
- HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE, Denver
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
被験者募集中第1/2相
- Sarah Cannon Research Institute at HealthONE, Denver
他の都市における悪性黒色腫の試験
- Houston, TX59件の研究
- New York City, NY38件の研究
- Los Angeles, CA34件の研究
- Nashville, TN33件の研究
- Pittsburgh, PA31件の研究
- Boston, MA26件の研究
- Philadelphia, PA23件の研究
- San Francisco, CA22件の研究
- Durham, NC21件の研究
- Atlanta, GA21件の研究
- St. Louis, MO21件の研究
- Salt Lake City, UT21件の研究
Denverにおける他の研究
- 転移性癌29件の研究
- 乳がん28件の研究
- 多発性骨髄腫27件の研究
- 非小細胞肺癌27件の研究
- 大腸癌23件の研究
- 前立腺がん19件の研究
- がん（全種類）18件の研究
- 卵巣がん16件の研究
- 肺がん16件の研究
- 子宮内膜がん15件の研究
- 非ホジキンリンパ腫14件の研究
- 膵臓がん13件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。